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Abstract: Identification of targetable molecular changes is essential for selecting appropriate
treatment in patients with advanced lung adenocarcinoma. Methods: In this study, a Sanger
sequencing plus Fluorescence In Situ Hybridization (FISH) sequential approach was compared
with a Next-Generation Sequencing (NGS)-based approach for the detection of actionable genomic
mutations in an experimental cohort (EC) of 117 patients with advanced lung adenocarcinoma. Its
applicability was assessed in small biopsies and cytology specimens previously tested for epidermal
growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational status, comparing
the molecular changes identified and the impact on clinical outcomes. Subsequently, an NGS-based
approach was applied and tested in an implementation cohort (IC) in clinical practice. Using Sanger
and FISH, patients were classified as EGFR-mutated (n = 22, 18.8%), ALK-mutated (n = 9, 7.7%),
and unclassifiable (UC) (n = 86, 73.5%). Retesting the EC with NGS led to the identification of at
least one gene variant in 56 (47.9%) patients, totaling 68 variants among all samples. Still, in the EC,
combining NGS plus FISH for ALK, patients were classified as 23 (19.7%) EGFR; 20 (17.1%) KRAS;
five (4.3%) B-Raf proto-oncogene (BRAF); one (0.9%) Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2); one
(0.9%) STK11; one (0.9%) TP53, and nine (7.7%) ALK mutated. Only 57 (48.7%) remained genomically
UC, reducing the UC rate by 24.8%. Fourteen (12.0%) patients presented synchronous alterations.
Concordance between NGS and Sanger for EGFR status was very high (κ = 0.972; 99.1%). In the IC, a
combined DNA and RNA NGS panel was used in 123 patients. Genomic variants were found in 79
(64.2%). In addition, eight (6.3%) EML4-ALK, four (3.1%), KIF5B-RET, four (3.1%) CD74-ROS1, one
(0.8%) TPM3-NTRK translocations and three (2.4%) exon 14 skipping MET Proto-Oncogene (MET)
mutations were detected, and 36% were treatable alterations. Conclusions: This study supports the
use of NGS as the first-line test for genomic profiling of patients with advanced lung adenocarcinoma.
Keywords: lung cancer; targeted therapy; next-generation sequencing; molecular profiling
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1. Introduction
Lung cancer is the most common cause of cancer-related death worldwide [1], being frequently
diagnosed in an advanced stage when curative treatment is no longer possible. Histologically, lung
cancer is divided into small and non-small cell lung cancer (NSCLC). NSCLC is the most common type
and includes squamous cell carcinoma, large-cell carcinoma and adenocarcinoma. Adenocarcinoma
subtype accounts for more than half and is further defined according to different molecular subtypes
by the identification of oncogenic drivers [2].
Over the last few decades, conventional platinum-based chemotherapy has produced only a modest
increase in patient´s overall survival, reaching a plateau, with response rates around 35% and median
survival time of 10–12 months [3]. Recent advances in the knowledge of NSCLC biology, especially on
the discovery of oncogenic molecular changes leading to aberrant activation of intracellular signalling
associated with the sustained growth of lung cancer cells, led to the development of genotype-targeted
therapies, with significant improvement in patient´s outcomes. For instance, the identification of
epidermal growth factor receptor (EGFR) kinase domain activating mutations, conferring sensitivity to
EGFR tyrosine kinases inhibitors, changed the lung cancer treatment paradigm and contributed to
increased progression-free survival (PFS) and quality of life in this subgroup of patients [4]. Targeted
therapy for patients with anaplastic lymphoma kinase (ALK) translocations had a similar impact
on prognosis [5]. In addition, the identification of other rare genomic alterations involving the ROS
Proto-Oncogene 1 (ROS1), B-Raf proto-oncogene (BRAF), MET Proto-Oncogene (MET), Erb-B2 Receptor
Tyrosine Kinase 2 (ERBB2), and ret proto-oncogene (RET) genes led to the development of new targeted
therapies, some already approved for first-line use [2–6]. Additionally, genomically unclassifiable (UC)
patients are candidates for immunotherapy with checkpoint inhibitors [6].
Updated recommendations from the College of American Pathologists, International Association
for the Study of Lung Cancer, Association for Molecular Pathology (CAP/IASCL/AMP), and European
Society of Medical Oncology (ESMO) have strengthened the 2013 guidelines and suggest genomic
testing for EGFR, ALK, and ROS1 for all advanced NSCLC, regardless of patients’ characteristics [7].
Besides, there is strong advise to perform broader molecular profiling for detection of rare mutations,
to which targeted therapies are available or suitable for off-label treatment or clinical trials (ERBB2,
MET, BRAF, KRAS, and RET) [8,9].
In the setting of lung cancer advanced disease, molecular diagnosis faces several difficulties.
Foremost, both the quantity and quality of tumor tissue and nucleic acid content are critical. Tissue
samples are often small histological fragments or cytological specimens obtained by bronchoscopy
or transthoracic biopsy. These samples should be analyzed for histopathology, which also includes
the programmed death-ligand 1 (PD-L1) test for immunotherapy selection and molecular testing [9].
The minimal conventional genomic study generally includes, sequentially or in parallel, at least,
the EGFR and ALK mutational analysis. Sequential determinations require a substantial DNA amount,
are time-consuming, cause sample´s exhaustion and often leads to under genotyping and treatment
delay [10,11].
Next-Generation Sequencing (NGS) allows the sequencing of several genomic regions in a single
test, in a single platform and even in samples with low DNA content. There are different NGS tests for
whole genome, whole exome, or selected genes, depending on the application purpose. An NGS-based
approach potentially provides a more sensitive and comprehensive genetic characterisation of lung
cancer, which may impact the therapeutic options and patient´s prognosis.
In this study, we tested an NGS-based approach for the detection of actionable genomic mutations
in a cohort of patients with advanced lung adenocarcinoma, previously tested sequentially for EGFR
and ALK mutational status, and evaluated the clinical impact of the NGS-based approach. The primary
endpoint was to assess the added-value of the NGS strategy over the sequential approach and the
concordance regarding the EGFR status. Additionally, the results from the clinical implementation of a
combined NGS DNA plus RNA panel are presented.
Cancers 2019, 11, 1229 3 of 14
2. Material and Methods
2.1. Study Design
A total of 240 patients with advanced lung adenocarcinoma, diagnosed in the Pulmonology
Department of Centro Hospitalar Universitário de São João (CHUSJ), EPE were enrolled in this study
and divided into two groups: (i) experimental cohort (EC), corresponding to patients diagnosed
between January 2015 and December 2016. Of a total of 127 patients previously examined for EGFR and
ALK mutational status, 117 had tumor samples available for NGS retest. Ten patients were excluded
from the study, seven owing to insufficient tumor sample, two with stage IIIA, and one included in
another trial; (ii) implementation cohort (IC), corresponded to 123 patients diagnosed from September
2017 to July 2018, to whom NGS was integrated into the daily clinical practice (Figure 1).
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Figure 1. Study design; 127 patients genomically profiled with sanger and anaplastic lymphoma kinase
(ALK) FISH test (standard approach) were selected. Among those, in 117 the same tu r sample
previously tested was submitted to Next-Generation S que cing (NGS), comprising the experimental
phase of the study (experimental cohort (EC)). Among the EC, * 22/117 were epidermal growth factor
receptor (EGFR) mutated and 95 had indication for anaplastic lymphoma kinase (ALK) testing, ** 17/95
patients did not perform it due to insufficient sample. After the EC, a combined DNA + RNA panel
was applied to characterize genomically patients with lung adenocarcinoma; 123 cases were included
for the purpose of this study (clinical implementation phase).
The tumor staging was based on the 7th edition of the TNM staging system until December 2017
and the 8th edition from January 2018 [12,13].
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All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of CHUSJ (CES-108/14).
2.2. Tumor Specimens
Biopsy and cytology specimens, from the primary tumor and metastatic sites, were reviewed by
pathologists. Histological specimens were fixed with formalin (formalin-fixed paraffin-embedded tissue,
FFPE) and cytological specimens as smears or cellblocks. After pathological and immunohistochemical
evaluation, samples were used for DNA extraction using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany), following manufacturer´s instructions. DNA was quantified with NanoDrop
Lite Spectrophotometer (Thermo Fisher Scientific™, Waltham, MA, USA) or Qubit® 2.0 Fluorometer
(Invitrogen, Waltham, MA, USA). All genetic analyses were done at IPATIMUP, a College of American
Pathologists and ISO15189 accredited laboratory.
2.3. Library and Template Preparation for Next-Generation Sequencing
The Ion AmpliSeq Colon and Lung Cancer Research Panel v2 (Ion Torrent, Waltham, MA, USA)
was used to detect changes in DNA, in the experimental phase. This multiplex PCR-based test allows
the analysis of 1850 hotspots and targeted regions in 22 genes (AKT1, ALK, BRAF, CTNNB1, DDR2,
EGFR, ERBB2, ERBB4, FBX7, FGFR3, FGFR1, FGFR2, KRAS, MAP2K1, MET, NOTCH1, NRAS, PTEN,
PIK3CA, STK11, SMAD4 and TP53) involved in tumorigenesis. Libraries were generated using 1–10 ng
of DNA from tissue FFPE blocks sections, according to the manufacturer.
In the clinical implementation phase, samples were characterised using the Oncomine Solid
Tumor kits CE-IVD (Ion Torrent, Waltham, MA, USA). These assays allow the analysis of the same
targets as the Ion AmpliSeq Colon and Lung Cancer Research Panel v2 plus the detection of ALK, RET,
ROS1, and NTRK1 gene fusions. Libraries were generated using 1–10 ng of DNA and RNA from tissue
FFPE blocks sections, according to the manufacturer. The final libraries were quantified by qPCR with
the Ion Library TaqMan® Quantitation Kit (Ion Torrent, Waltham, MA, USA) and used for template
preparation performed using the Ion Chef (Ion Torrent, Waltham, MA, USA).
2.4. Next-Generation Sequencing and Bioinformatic Analysis
Loaded chips were sequenced in an Ion PGM or Ion S5XL sequencer. Sequencing quality was
assessed through the plug-in coverage analysis and the samples were analyzed using dedicated
bioinformatic workflows within the Ion Reporter v5.6 server (Ion Torrent, Waltham, MA, USA).
Samples with a number of reads <100,000 and/or the average base coverage <500×were considered
inadequate for analysis. The amplicons with a coverage <250× were considered non-informative.
Mutations with allele frequencies of at least 10% and adequate coverage in target regions were
considered to call a mutation in a patient sample. Polymorphisms, synonymous or intronic mutations
were excluded. The Catalogue of Somatic Mutations in Cancer (COSMIC) database was used to access
the clinically relevant variants. Some mutations detected by NGS were validated by digital PCR.
2.5. Statistical Analysis
The sample size was limited by the availability of specimens for subsequent NGS analysis
following sequential standard molecular diagnostic approach. Most of the analysis was descriptive.
Categorical data were described as absolute (n) and relative frequencies. Medians, interquartile ranges
(IQR), and minimum and maximum values were determined for continuous variables. The NGS
results were correlated with other parameters and assessed with the chi-square test or Fisher´s exact
test, when appropriate. Cohen´s Kappa test was used to assess the inter-rater agreement for categorical
data. Kaplan-Meier actuarial curve analysis was used to assess survival and the log-rank test for the
chi-square (X2) calculus, for each event time and each evaluated group. The significance level assumed
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was 0.05. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS,
IBM Corp, Chicago, IL, USA) software, version 25.0.
3. Results
3.1. Clinicopathologic Characteristics and Mutational Profile
In this study, 117 and 123 patients were, respectively, included in the EC and IC groups.
The clinicopathologic features are presented in Table 1. All specimens were adenocarcinoma, except one
suggestive of adenosquamous carcinoma (in the EC). Most of patients had stage IV disease at the time of
diagnosis. In both groups, samples were predominantly core biopsies suitable for histological analysis.
Cytological samples were obtained by fine-needle-aspiration techniques, as pleural and pericardial
fluid aspiration, endobronchial ultrasound-guided needle aspiration (EBUS-TBNA), and lung and
peripheral lymph nodes fine-needle aspirations (Table 1).
Table 1. Patient´s demographics and clinical characteristics.
Characteristics EC Value(n, %)
IC Value
(n, %) p Value
Age (median, range) 66 (38, 92) 67 (41, 94) 0.320
Gender
Male 71 (60.7) 77 (62.6)
0.760Female 46 (39.3) 46 (37.4)
Performance
status
0 42 (35.9) 61 (49.6)
0.055
1 53 (45.3) 38 (30.9)
2 16 (13.7) 13 (10.6)
3 6 (5.1) 11 (8.9)
Smoking status Smoker/Former Smoker 74 (63.2) 82 (66.7) 0.579Never smoker 43 (36.8) 41 (33.3)
Disease stage III (A/B/C) 22 (18.8) 23 (18.7) 0.984IV 95 (81.2) 100 (81.3)
Histology Adenocarcinoma 116 (99.1) 123 (100) 0.304Adenosquamous 1 (0.9) 0
TTF1 IHQ
Positive 101 (86.3) 100 (81.3)
0.070Negative 5 (4.3) 15 (12.2)
Unknown 11 (9.4) 8 (6.5)
Specimen type
Histologic
Bronchial 31 (26.5) 22 (17.8)
0.487
Lung 51 (43.6) 63 (51.2)
Pleura 10 (8.5) 7 (5.7)
Brain 2 (1.7) 5 (4.1)
Bone 2 (1.7) 1 (0.8)
Liver 0 2 (1.6)
Lymph node 0 3 (2.4)
Skin 0 1 (0.8)
Small bowel 0 1 (0.8)
Total 96 (82.1) 105 (85.4)
Cytologic
Lung-FNA 2 (1.7) 0
EBUS-FNA 2 (1.7) 2 (1.6)
Pleural fluid 12 (10.2) 10 (8.1)
Pericardial fluid 1 (0.9) 0
Bronchial washing or
brushing 0 4 (3.2)
Lymph node 4 (3.4) 2 (1.6)
Total 21 (17.9) 18 (14.6)
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Table 1. Cont.
Characteristics EC Value(n, %)
IC Value
(n, %) p Value
Molecular status
(Standard
approach)
EGFR Mutated 22 (18.8)
ALK EML4-ALK 9 (7.7)
UC 86 (73.5)
Total 117 (100)
FNA, Fine-needle aspiration; UC, unclassifiable.
NGS analysis succeeded in both histological and cytological samples, with no statistically
significant differences between groups (p = 0.487). The frequency of alterations found did not differ in
both histological and cytological samples between both cohorts. In the EC, 7/21 mutations were from
cytological samples and 49/96 in histological samples (p = 0.141). In the IC, hotspot alterations were
found in 12/18 cytological and 66/105 histological samples (p = 0.538).
In the EC, the EGFR mutation test was performed in all patients, with a positive rate of 18.8% (22/117).
ALK translocations were identified in 7.7% of cases (9/117) (Table 1). The remaining cases were designated
as UC (n = 86, 73.5%). Of the 95 EGFR negative cases with ALK FISH testing indication, 17.9% (17/95) had
insufficient sample for ALK test. EGFR-mutated patients were distributed as follows: 16 (72.7%) exon19
deletions (19 DEL), five (22.7%) L858R, and one (4.5%) exon20 insertion (20 Ins) (Table S1).
3.2. Next-Generation Sequencing Results
According to the results obtained with the Ion AmpliSeqTM Colon and Lung Cancer Research
Panel v2 for DNA analysis, 56 (47.9%) patients harbored at least one gene variant and in 61 (52.1%)
no genomic alteration was identifiable, remaining as UC. Analyzing by patient and comparing with
the standard approach (Figure 2A), the most frequent alterations were KRAS (n = 23, 19.7%), EGFR (n
= 23, 19.7%), BRAF (n = 5, 4.3%), TP53 (n = 3, 2.6%), ERBB2 (n = 1, 0.9%), and STK11 (n = 1, 0.9%).
Analyzing by sample, a total of 68 genomic variants were identified (Figure 2B; Table S2).
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Of the 86 (73.5%) patients classified as UC by the standard approach, 29 (33.7%) had at least
one gene alteration. Beyond EGFR mutations, variants were observed in other targetable genes, as
described above. Two additional EGFR mutations were found, one not previously identified and one
as co-alteration.
Combining NGS for DNA analysis data plus ALK detection by FISH, 60 (51.3%) patients had at
least one alteration identified, and 57 (48.7%) remained without identified mutations, reducing the UC
rate by 24.8% (Figure 3A,B).
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3.3. Concurrent Genomic Alterations
Concurrent changes were found in 14 patients (12.0%) (Table 2), with emphasis on co-alterations
occurring in EGFR (4/23) and ALK (5/9) mutated patients. Among the EGFR mutated patients,
one exhibited an ALK point mutation c.3512T>A in a neglectable percentage; one patient, with a
combination of Del19 with allelic frequency of 66% plus p.T790M with allelic frequency of 0.6%, had a
PFS with a 1st generation TKI of 9.2 months and progressed with the p.T790M point mutation; the
other two patients had a KRAS mutation and a PIK3CA mutation, respectively. In the ALK-positive
patients’ subgroup, a molecular co-alteration was detected in five cases: three with KRAS and two
with TP53 mutations. Two of the ALK plus KRAS mutated patients had a very dismal evolution with
overall survival (OS) less than 3 months (Table 2).
Table 2. Cases with concomitant genomic alterations.
Patient’s
Classification
(Standard Approach)
NGS Genomic Alteration AF ClinicalSignificance PFS1 OS
UC
KRAS c.35G > T 26.7 Pathogenic
7.1 9TP53 c.839G > A 13.0 Likely pathogenic
UC
BRAF c.1799T > A 50.4 Pathogenic
4 15TP53 c.476C > G 39.2 Uncertain
UC
KRAS c.182A > G 8.8 Pathogenic
2 5TP53 c.461G > T 24.7 Uncertain
STK11p.Glu199Asp 12.8 Pathogenic
UC
ERBB2 c.2310_2311insGCATAC 20 Not found
0 3TP53 c.1024C > T 21 Pathogenic
UC
KRAS c.38_39delGCinsAA 14.2 n/a
0 4ERBB4 c.1033G > T 14.9 n/a
EGFR
EGFR c.2235_2249del15 34.6 Pathogenic
10.1 37 (NR)PIK3CA c.1633G > A 27.8 Pathogenic
EGFR
EGFR c.2236_2250del15 11.1 Pathogenic
8 24KRAS c.182A > G 0.38 Pathogenic
EGFR
EGFR c.2240_2257del18 67.2 Pathogenic
9.4 40 (NR)EGFR c.2369C > T 0.6 Pathogenic
EGFR
EGFR c.2239_2248del 66 Pathogenic
16.6 NRALK c.3512T > A 0.08 Pathogenic
EML4-ALK TP53 c.538G > T 37.8 Pathogenic 9.7 42
EML4-ALK TP53 c.524G > A 2.13 Pathogenic 16 31
EML4-ALK KRAS c.35G > T 27.4 Pathogenic NE 3
EML4-ALK KRAS c.35G > T 11.7 Pathogenic 7 47
EML4-ALK KRAS c.35G > A 6.1 Pathogenic NE 2
UC, unclassifiable; AF, allelic frequency; PFS1, Progression Free Survival related to 1st Line therapy; OS, Overall
survival, NE, not evaluated; NR, not reached: n/a, not available.
3.4. Concordance Between Sanger and NGS for the EGFR Status
A set of 117 patients was analyzed by both Sanger sequencing and NGS for EGFR mutations
detection, allowing the concordance determination between tests. Overall, the percentage of concordant
cases was 116/117 (99.1%) (Table 3), and there was an almost perfect agreement between the two tests
(κ = 0.972; p < 0.001).
Assuming that all EGFR positive cases are true positives, in this cohort, 23 patients were EGFR
mutated. The sensitivity for Sanger was 95.6% and for NGS 100%. One extra EGFR mutated patient
was found among the unclassified population by Sanger.
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Table 3. Comparison between NGS and Sanger for EGFR status.
Gene Cases Compared (n)
Concordant Results
SS vs. NGS
Discordant
SS vs. NGS Concordant Cases (%) Kappa
Neg/Neg Pos/Pos Neg/Pos Pos/Neg
EGFR 117 94 22 1 0 99.1 0.972
NGS, next-generation sequencing; SS, Sanger sequencing.
3.5. Impact of the Identification of Targetable Alterations in Patient’s Overall Survival
The EC presented a median OS of 13.0 months (95% CI 8.1–17.9, sd = 2.5): 24 months (95% CI
10.2–37.8, sd = 7.0) for the EGFR subgroup, 11 months (95% CI 5.2–16.8, sd = 2.98) for ALK, and 11
months for UC patients (95% CI 5.98–16.0, sd = 2.6). Specific survival patterns were observed in
subtypes of oncogenic alterations detected by NGS, with EGFR patients having the best median OS
and KRAS the worse (Figure 4A). Among patients with a druggable oncogenic alteration, 30 were
treated with targeted therapy, 21/23 EGFR, 2/5 BRAF, 7/9 (ALK) were treated with TKIs. Regardless
of the treatment line, OS was significantly higher for this subgroup of patients (median OS 24 vs. 9
months, p = 0.028) (Figure 4B). As groups were small, no statistical comparisons were feasible.
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3.6. NGS Results from the Implementation Cohort with a Combined DNA and RNA Panel
Combined DNA and RNA sequencing succeeded in 117 (95.1%). DNA degradation occurred in
four (3.2%) cases and in these cases, EGFR was analyzed by Sanger sequencing. RNA extraction failed
in two cases (1.6%), with no statistically significant differences in the sequence rate according to the
sample type (16/18 for cytology and 102/105 for histology, p = 0.1).
DNA and RNA hotspot alterations were detected in 79 (64.2%) patients. KRAS mutations occurred
in 33 (26.8%) patients, EGFR in 18 (14.6%), BRAF in four (3.2%), ERBB2 in five (4.1%), and PIK3CA
in one (0.8%). Exon 14 skipping MET mutation was detected in three (2.4%) patients. Considering
gene translocations, eight (6.5%) patients had an ELM4-ALK, four (3.1%) an KIF5B-RET, one (0.8%)
an CD74-ROS1, and one (0.8%) an TPM3-NTRK (Figure 3C and Table S3). Only 44 (35.8%) patients
remained as UC. Forty-four (35.8%) patients had treatable alterations. Additionally, co-alterations were
found in 11 (8.9%) cases (Table S4).
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4. Discussion
Lung cancer treatment is rapidly evolving from histology to precision-based therapy, relying on
predictive biomarkers determined by molecular tests. Sequential analysis of each gene with single-gene
assays is unable to search efficiently for all actionable mutations, due to tumor sample extinction.
For completing the minimum genomic characterisation, patients would have to undergo additional
diagnostic procedures, with increased risk and costs. Testing each biomarker, one at a time, may result
in longer and potentially unacceptable turnaround time. Besides, and considering the number of genes
that must be tested, it will probably not be cost-effective.
Lung cancer diagnosis is established predominantly in small biopsies or cytological samples,
which must be enough for morphology, immunohistochemistry (IHC), and molecular evaluation,
essential to determine if an actionable oncogenic alteration is present. In real-world clinical practice,
many obstacles arise to meet this need. The barriers consist of cost, number of separate assessments
required, quality of tumor samples and local availability of the tests [14,15].
In the last years, Sanger sequencing has been considered the gold standard for gene mutation
testing, particularly, for EGFR. However, this technique is not very sensitive, requires samples with at
least 20% of tumor cells and its application to small lung biopsies or cytology specimens is not always
possible. In addition, to assess ALK rearrangements, the gold standard is IHC or FISH, both tests
needing many histological sections from an FFPE or a cellblock.
High-throughput NGS, also referred to as massively parallel sequencing, allows multiplex PCR
with simultaneous amplification of a pre-specified panel of genes in a single reaction. Depending on
the panel, it offers the possibility to analyze DNA, RNA, transcription regions, methylation patterns
and, more recently, tumor mutation burden. Targeted gene panels represent an alternative method for
capturing specific genomic regions for subsequent sequencing and is the best option for molecular
characterization of lung cancer, allowing multiple genes to be analyzed at the same time with enough
depth of coverage to detect minor allele frequencies. Most NGS assays require as little as 10 ng of DNA,
or even less, while non-NGS tests, like Sanger, require more DNA. NGS was previously validated in
several studies and its superiority is recognised in terms of sensitivity, speed, and costs [16–19].
In the present study, we report our experience with a targeted NGS-based strategy, using the
Thermofisher Ion Torrent NGS technology, with the Ion AmpliSeq Colon and Lung Cancer Research
Panel v2, for the detection of actionable genomic alterations in a cohort of patients with lung
adenocarcinoma, and the steps taken until its prospective integration into our clinical practice. This
panel was previously validated in a study, in which the same sample was tested in seven different
laboratories of the OncoNetwork Consortium [20]. In our study, tumor specimens were previously
analyzed for the determination of EGFR and ALK mutational status, by Sanger sequencing and FISH,
respectively, according to recommendations at that time [7]. After morphological and molecular
standard subtyping, samples were retested with the targeted-gene NGS panel. NGS was done in
samples with an average of 5.1 ng DNA, suggesting that successful sequencing may occur in samples
with small DNA amounts, overcoming the difficulty of mutation analysis in the context of lung cancer
diagnosis [15].
In our cohort, only 77 (65.8%) patients had both EGFR and ALK genes analyzed, reflecting the
difficulty in completing the minimal recommended genomic analysis, based on single sequential tests,
as previously mentioned. The specimens were diverse and the Ion Ampliseq sequencing proved to
be effective even in critical samples, such as those obtained by FNA and biological fluids. Scarpa et
al. [21] demonstrated, for the first time, the successful application of the Ion AmpliSeq Colon and
Lung Cancer in cytological samples of lung adenocarcinoma, and these results were replicated in other
studies [14,22–24].
NGS revealed excellent accuracy for EGFR detection and a very high concordance rate (99.1%) with
Sanger sequencing. There was only one discordant case, an EGFR deletion (EGFR c.2236_2250del15)
detected with NGS but missed by Sanger. Indeed, previously published studies have also highlighted
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the NGS superiority over the traditional methods [25–27]. Although not an epidemiological study,
mutation patterns and frequencies agree with previous data published on our population [28].
Our data demonstrated high sensitivity to detect druggable alterations, significantly reducing the
rate of genomically unclassifiable patients to 48.7%, with the combination of the Ion Ampliseq panel
and ALK FISH test. Additionally, we identified molecular changes in 29/86 (33.7%) of the UC patients
classified by the standard approach, as reported in similar studies [29,30]. Beyond KRAS mutations,
one more patient with an EGFR activating mutation and five with BRAF-p.V600E could have been
treated with targeted agents or included in clinical trials.
NGS also provided some insights into the biology and clinical behavior of the disease. According
to the survival analysis, subsets of patients could be defined: EGFR-mutated patients presented higher
median OS and KRAS the lowest ones, which is similar to the literature data [31,32]. Unexpectedly,
ALK patients had a low OS, perhaps due to the unavailability of TKIs as first-line treatment at the
beginning of the study and to the coexistence of KRAS mutation in three of the nine ALK patients.
This occurrence is rare, but it has already been reported as being associated with primary resistance
to TKIs [32,33]. The expected co-occurrence of TP53 mutations with KRAS, EGFR, BRAF, PIK3CA,
and STK11 were also identified. Another interesting finding was the detection, before treatment, of a
low allelic frequency p.T790M point mutation alongside the driver Del19, which, in this case, prompted
progression through this on-target resistance mechanism. The identification of simultaneous alterations
can explain the unexpected clinical outcomes and resistance patterns, suggesting the existence of
subclonal populations or hypothetically a different population of tumor cells. Considering the small
sample size of this study, definitive conclusions on the clinical impact of a concurrent genomic alteration
cannot be driven and deserve further investigation.
After the evaluation phase of this DNA panel, since it has limitations regarding chromosomal
rearrangements detection, a combined DNA and RNA panel, Ion TorrentTM Oncomine™ Focus
Assay [34], was integrated into the lung cancer molecular diagnosis. This panel allowed even a higher
reduction of unclassified patients to 36%. In this clinical cohort, beyond the target point mutations and
deletions found, exon 14 skipping MET mutation and gene translocations, ELM4-ALK, KIF5B-RET,
CD74-ROS1, and even a TPM3-NTRK were detected. Overall, in the clinical cohort, and considering
drug’s availability, about 36% of patients were candidates for specific therapy. These data demonstrate
that this combined targeted NGS sequencing methodology allows the detection of common and some
clinically relevant rare mutations. This strategy can identify more patients who are likely to benefit
from specific therapies, improving clinical outcomes, minimising the toxic effects, and promoting
drug development.
Our data are equivalent to those obtained in larger studies. In the Lung Cancer Consortium, an
actionable oncogenic alteration was found in 64% of patients [30]. In a study made by Foundation
Medicine, 6.832 clinical NSCLC samples were tested with a comprehensive hybridization capture
panel with more than 300 genes, able to detect also translocations, and 71% of patients harbored at
least one genomic alteration [35].
This study was practice changing. The routine diagnostic workup is, at present, a reflex test
including IHC, PDL1, and a combined DNA and RNA next-generation sequencing on FFPE tissue or
cytological samples, for all patients with NSCLC with genomic testing indication. This analysis was
mainly focused on the clinical usefulness of NGS, in search of suitable patients for targeted approved
drugs, off-label treatments and clinical trials, but the spectrum of applications goes further beyond
that. This kind of combined panel, profiling DNA and RNA, has also the potential to detect alterations
that may soon have available drugs and the ability to identify and further characterize resistance
mechanisms and aberrant clinical patterns. Future challenges will be the interpretation of co-alterations,
low-frequency variants, and those of uncertain biological meaning.
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5. Conclusions
This study contributed to the clinical validation of NGS for screening actionable mutations
in patients with lung adenocarcinoma, demonstrating good accuracy in biological specimens with
small DNA content, like those obtained for lung cancer diagnosis. In addition, it provided a
more comprehensive genomic characterisation of the disease, contributing to a better definition of
tumor biology.
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